Scinai Immunotherapeutics (SCNI) Research & Development (2014 - 2024)

Scinai Immunotherapeutics has disclosed Research & Development across 11 years of filings, most recently posting $9.7 million for Q4 2024.

• Research & Development for Q4 2024 came in at $9.7 million, up 1451.36% year-over-year; the trailing twelve-month figure through Dec 2024 was $8.3 million (up 183.68% YoY), and the FY2025 annual result was -$2.4 million, down 142.82% from the prior year.
• Research & Development came in at $9.7 million for Q4 2024 at Scinai Immunotherapeutics, up from $1.4 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $19.1 million in Q1 2020 to a low of -$4.4 million in Q2 2024.
• The 5-year median for Research & Development is $1.5 million (2023), against an average of $3.0 million.
• Peak annual rise in Research & Development reached 1451.36% in 2024, while the deepest fall reached 399.59% in 2024.
• Scinai Immunotherapeutics' Research & Development stood at $7.9 million in 2020, then tumbled by 143.57% to -$3.4 million in 2021, then jumped by 141.83% to $1.4 million in 2022, then slumped by 56.28% to $627000.0 in 2023, then surged by 1451.36% to $9.7 million in 2024.
• The last three Research & Development figures came in at $9.7 million (Q4 2024), $1.4 million (Q3 2024), and -$4.4 million (Q2 2024), per Business Quant data.